CDK9


Also found in: Acronyms, Wikipedia.

CDK9

A gene on chromosome 9q34.1 that encodes a cyclin-dependent kinase, which regulates cell cycle progression. CDK9 is part of the multiprotein complex TAK/P-TEFb, an elongation factor for RNA polymerase II-directed transcription, which acts by phosphorylating the C-terminal domain of a subunit of RNA polymerase II. 

Molecular pathology
HIV-1 Tat protein interacts with CDK9 and cyclin T, suggesting CDK9 may have a role in AIDS.
Mentioned in ?
References in periodicals archive ?
A rabbit polyclonal CDK9 antibody from Abcam at 1:1600 dilution was used in the immunohistochemistry (IHC) staining process.
Tambien se ha observado que los niveles de CDK9 son similares entre los monocitos y los macrofagos (42); sin embargo, estos ultimos poseen mayor expresion de CDK9 fosforilada, que es importante para la activacion del P-TEFb (37).
"Alternatively, by harnessing Brd4 or Cdk9, we may be able to drive cells out of latency and make the virus susceptible to anti-HIV drugs."
Inhibition of CDK9 has been shown to block MCL-1 transcription, resulting in the rapid downregulation of MCL-1 protein, thus restoring the normal apoptotic regulation.
Presentations will also show our progress within Tumour Drivers and Resistance with the development of molecules targeting two key mechanisms that tumours use to resist cell death, namely MCL-1 and CDK9.'
Biopharmaceutical Company Probiodrug, based in Germany has announced that it has transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca.
M2 EQUITYBITES-January 6, 2014-Probiodrug AG reports transfer of CDK9 inhibitor programme under asset purchase agreement
has tabulated preliminary data from Zella 201, an ongoing Phase 2 study evaluating the efficacy and safety of alvocidib, an investigational small molecule cyclin-dependent kinase 9 (CDK9) inhibitor, in combination with cytarabine and mitoxantrone in patients with relapsed or refractory myeloid cell leukemia 1 (MCL-1) dependent acute myeloid leukemia (AML), the company said.
M2 EQUITYBITES-January 3, 2014-Probiodrug divests its CDK9 Inhibitor Programme to AstraZeneca for undisclosed sum
M2 PHARMA-January 6, 2014-Probiodrug AG reports transfer of CDK9 inhibitor programme under asset purchase agreement
M2 PHARMA-January 3, 2014-Probiodrug divests its CDK9 Inhibitor Programme to AstraZeneca for undisclosed sum
In multiple myeloma, the addition of ERK5 inhibition and the established roles of the JAK-STAT and CDK9 pathways in myeloma cell survival and drug resistance suggest that TG02 could be an exciting addition to the armamentarium for this disease, added Dr Zaknoen.